News
Discover our articles and industry news
Is Pharmacovigilance Mandatory ? Understanding Regulatory Obligations for Pharmaceutical Companies and Service Providers
💊 Patient safety is a fundamental priority throughout a medicinal product's lifecycle. This is why…
Monitoring the European clinical trials environment
June 2, 2026
Monitoring the European clinical trials environment
The Accelerating Clinical Trials in the EU (ACT EU) initiative has published a report “Monitoring…
Trust and transparency
May 29, 2026
Trust and transparency
🔬 In pharmacovigilance, trust is more than a value — it is the foundation of…
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2026
May 26, 2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2026
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its May 2026 meeting.
EMA meets pharmaceutical leaders to discuss the future direction of the EU pharmaceutical system
May 19, 2026
EMA meets pharmaceutical leaders to discuss the future direction of the EU pharmaceutical system
The European Medicines Agency (EMA), together with Heads of Medicines Agencies (HMA), met senior executives…
FAQ updated for the CTIS training programme
May 15, 2026
FAQ updated for the CTIS training programme
The European Medicines Agency (EMA) has published an updated FAQ for the Clinical Trials Information…
CMDh publishes Guidance on the Informal Work-Sharing procedure for follow-up for PSUSA for NAPs
May 7, 2026
CMDh publishes Guidance on the Informal Work-Sharing procedure for follow-up for PSUSA for NAPs
Occasionally, it may not be possible to finalise an issue (e.g. a signal or a…
What if how you feel after taking a medication really mattered?
After taking a medication, you may notice something unusual: extreme tiredness, headaches, rashes, nausea… 👉…
Product Management Service (PMS) – Frequently Asked Questions (FAQs)
The European Medicines Agency (EMA) has published a list of frequently asked questions (FAQs) collected…
💊 Every report matters. Every signal counts
April 23, 2026
💊 Every report matters. Every signal counts
Behind every medicine, there’s continuous monitoring to ensure safety for all. From rare side effects…
EMA publishes detailed guidance on electronic submission of authorized medicines
The European Medicines Agency (EMA) has published detailed XEVPRM user guidance on the electronic submission…
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 April 2026
April 17, 2026
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 April 2026
The meeting highlights were published. PRAC agrees on communication to inform healthcare professionals that cases…
Behind each safe medication, there is a PV expert who analyses, prevents and protects
April 16, 2026
Behind each safe medication, there is a PV expert who analyses, prevents and protects
🔍 Discover the crucial role played by our experts at Pharmya, 🛡️ And how they…
EMA’s Data Protection Notice for the exchange of information during the Critical Medicines Vulnerability Assessment exercise
April 9, 2026
EMA’s Data Protection Notice for the exchange of information during the Critical Medicines Vulnerability Assessment exercise
The European Medicines Agency (EMA) has published a Data Protection Notice explaining the details of…
Social Media and Pharmacovigilance 📱💊
March 31, 2026
Social Media and Pharmacovigilance 📱💊
In the digital age, social media has become an essential tool for healthcare professionals and…
World Tuberculosis Day : a major public health and pharmacovigilance challenge
🌍 World Tuberculosis Day : a major public health and pharmacovigilance challenge 🦠 Tuberculosis…
